Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (25)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Carrillo-Muñoz, A. J.
Right arrow Articles by Wallace, T. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Carrillo-Muñoz, A. J.
Right arrow Articles by Wallace, T. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (1999) 44, 397-401
© 1999 The British Society for Antimicrobial Chemotherapy

Brief report

In-vitro antifungal activity of liposomal nystatin in comparison with nystatin, amphotericin B cholesteryl sulphate, liposomal amphotericin B, amphotericin B lipid complex, amphotericin B desoxycholate, fluconazole and itraconazole

A. J. Carrillo-Muñoza,*, G. Quindósb, C. Tura, M. T. Ruesgab, Y. Mirandab, O. del Vallec, P. A. Cossumd and T. L. Wallaced

a Department of Microbiology, Asesoría Científica y de Investigación Aplicada, E-08031 Barcelona b Department of Microbiology and Parasitology, School of Medicine, University of the Pais Vasco, Bilbao c Service of Microbiology, Hospital Vall dóHebrón, Barcelona, Spain d Pre-Clinical Research and Development, Aronex Pharmaceuticals Incorporated, The Woodlands, TX, USA

The in-vitro susceptibilities of 120 clinical isolates of yeasts to liposomal nystatin were compared with those to amphotericin B lipid complex (ABLC), liposomal amphotericin B (LAB), amphotericin B cholesteryl sulphate (ABCD), amphotericin B desoxycholate, nystatin, fluconazole and itraconazole. Yeast isolates examined included strains of Candida albicans, Candida parapsilosis, Candida glabrata, Candida krusei, Candida guilliermondii, Candida tropicalis, Candida kefyr, Candida viswanathii, Candida famata, Candida rugosa, Rhodotorula rubra, Trichosporonspp., Cryptococcus laurentii and Cryptococcus neoformans. The mean MICs for all strains examined were: liposomal nystatin 0.96 mg/L; nystatin 0.54 mg/L; ABLC 0.65 mg/L; LAB 1.07 mg/L; ABCD 0.75 mg/L; amphotericin B 0.43 mg/L; fluconazole 5.53 mg/L; and itraconazole 0.33 mg/L. No significant differences were seen between the activity of liposomal nystatin and the polyene drugs or itraconazole, but liposomal nystatin was more active than fluconazole. MICs were lower than the reported blood concentrations following therapeutic doses of this drug, indicating the potential for a therapeutic use of liposomal nystatin in humans. These results indicate good activity in vitroagainst medically important yeasts, which compares favourably with the activities of other currently available antifungal drugs. Liposomal nystatin may have a role in the treatment of disseminated and systemic mycoses.

* Corresponding author. Fax: +34-93-429-71-20; E-mail: ajcm.acia{at}bcn.servicom.es


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Clin. Microbiol.Home page
S. S. Richter, R. P. Galask, S. A. Messer, R. J. Hollis, D. J. Diekema, and M. A. Pfaller
Antifungal Susceptibilities of Candida Species Causing Vulvovaginitis and Epidemiology of Recurrent Cases
J. Clin. Microbiol., May 1, 2005; 43(5): 2155 - 2162.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
F. Offner, V. Krcmery, M. Boogaerts, C. Doyen, D. Engelhard, P. Ribaud, C. Cordonnier, B. de Pauw, S. Durrant, J.-P. Marie, et al.
Liposomal Nystatin in Patients with Invasive Aspergillosis Refractory to or Intolerant of Amphotericin B
Antimicrob. Agents Chemother., December 1, 2004; 48(12): 4808 - 4812.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
A. H. Groll, D. Mickiene, V. Petraitis, R. Petraitiene, R. M. Alfaro, C. King, S. C. Piscitelli, and T. J. Walsh
Comparative Drug Disposition, Urinary Pharmacokinetics, and Renal Effects of Multilamellar Liposomal Nystatin and Amphotericin B Deoxycholate in Rabbits
Antimicrob. Agents Chemother., December 1, 2003; 47(12): 3917 - 3925.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
J. A. Wasylnka and M. M. Moore
Uptake of Aspergillus fumigatus Conidia by Phagocytic and Nonphagocytic Cells In Vitro: Quantitation Using Strains Expressing Green Fluorescent Protein
Infect. Immun., June 1, 2002; 70(6): 3156 - 3163.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
S. Arikan, L. Ostrosky-Zeichner, M. Lozano-Chiu, V. Paetznick, D. Gordon, T. Wallace, and J. H. Rex
In Vitro Activity of Nystatin Compared with Those of Liposomal Nystatin, Amphotericin B, and Fluconazole against Clinical Candida Isolates
J. Clin. Microbiol., April 1, 2002; 40(4): 1406 - 1412.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
J. Meletiadis, J. F. G. M. Meis, J. W. Mouton, J. L. Rodriquez-Tudela, J. P. Donnelly, and P. E. Verweij
In Vitro Activities of New and Conventional Antifungal Agents against Clinical Scedosporium Isolates
Antimicrob. Agents Chemother., January 1, 2002; 46(1): 62 - 68.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
L. Ostrosky-Zeichner, S. Bazemore, V. L. Paetznick, J. R. Rodriguez, E. Chen, T. Wallace, P. Cossum, and J. H. Rex
Differential Antifungal Activity of Isomeric Forms of Nystatin
Antimicrob. Agents Chemother., October 1, 2001; 45(10): 2781 - 2786.
[Abstract] [Full Text]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.